Tag Archives: antibody
What type of immune responses are needed to control HIV infection?
Human immunodeficiency virus-1 (HIV-1) infection can be controlled by antiretroviral therapy (ART) for long periods of time, preventing the development of HIV-induced immunodeficiency and AIDS. However, HIV-1 infection cannot be eradicated from immune cells by ART and
Fully human anti-CAIX antibodies for RCC immunotherapy
Globally, there are roughly 270,000 new cases and 116,000 deaths attributed to kidney cancer occur each year. More than 90% of kidney neoplasms are classified as renal cell carcinoma (RCC), which accounts for 3% of all adult
Could cancer be cured by inducing an autoimmune disease against It?
Might there be some way to make a microbial protein that the immune system normally overlooks (a “non-antigen”) into a target for an active immune response (an “antigen”)? Could one co-opt the immune system to produce an
Characterizing the whac-a-mole concept of a bispecific antibody targeting cancer cells
One of the great promises of antibodies is to be magic bullets that specifically target diseased cells without affecting normal cells. Oncology researchers identify targets on tumor cells that are unique, overexpressed, or oncogenic drivers that can
A electrochemical biosensor for the detection of antibodies against avian influenza virus type H5N1 in hen sera
Avian influenza (AI) is a highly contagious disease caused by Orthomyxoviridae family viruses. Highly pathogenic avian influenza (HPAI) virus can be easily transmitted between poultry, leading to severe disease outbreaks or even pandemics. It is difficult to
Combining different antibody flavors to improve cancer therapy
Our immune system is specialized at identifying ‘foreign intruders’ (pathogens) or virus-infected cells inside the human body. This can be achieved by antibodies (immunoglobulins) that circulate in our body and are able to bind targets with high
Reactivation of neutralized HIV-1 by dendritic cells
HIV-1 can be bound by neutralizing antibodies that target the envelope glycoprotein (Env) and thereby block viral entry into HIV-1 susceptible cells. HIV-1 specific antibodies are formed within the first two weeks in patients, but usually these
